Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Basic): 2022-2025

Historic EPS (Basic) for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to -$8.36.

  • InMed Pharmaceuticals' EPS (Basic) rose 83.76% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.45, marking a year-over-year increase of 52.78%. This contributed to the annual value of -$8.36 for FY2025, which is 58.49% up from last year.
  • As of FY2025, InMed Pharmaceuticals' EPS (Basic) stood at -$8.36, which was up 58.49% from -$20.14 recorded in FY2024.
  • Over the past 5 years, InMed Pharmaceuticals' EPS (Basic) peaked at -$3.25 during FY2023, and registered a low of -$33.17 during FY2022.
  • For the 3-year period, InMed Pharmaceuticals' EPS (Basic) averaged around -$10.58, with its median value being -$8.36 (2025).
  • In the last 5 years, InMed Pharmaceuticals' EPS (Basic) soared by 90.20% in 2023 and then plummeted by 519.69% in 2024.
  • InMed Pharmaceuticals' EPS (Basic) (Yearly) stood at -$33.17 in 2022, then soared by 90.20% to -$3.25 in 2023, then slumped by 519.69% to -$20.14 in 2024, then spiked by 58.49% to -$8.36 in 2025.